The new frontier in obesity care for seniors

While obesity prevalence has nearly doubled to 40% among Americans over 65, only 9% of Medicare beneficiaries currently use GLP-1s—compared with 22% of those aged 50–64. This is because many clients have regained their health through GLP-1 therapy, only to realize this coverage might vanish the moment they blow out 65 candles. It is a heartbreaking scenario, but as advisors, we have the power to change that narrative.

For years, the Medicare Modernization Act of 2003 has served as a statutory barrier, explicitly prohibiting Part D coverage for weight-loss drugs, but 2026 is set to change this.

We are entering an era in which obesity care is finally recognized as a cornerstone of cardiovascular health rather than a lifestyle choice. Here is how I am navigating this new frontier to keep my clients protected and their retirement plans on track.

Leveraging the $2,100 Medicare out-of-pocket prescription cap

The Inflation Reduction Act has provided us with an incredibly powerful planning tool for 2026. Medicare Part D enrollees now benefit from a $2,100 out-of-pocket maximum, a significant shift that makes high-cost drug spending far more predictable. Clients who qualify for GLP-1 coverage for cardiovascular health will likely hit this limit within the first few months of the year.

I use this cap to show my clients how their health care costs can essentially drop to zero for the remainder of the year once the threshold is met. You should emphasize that once you reach the $2,100 limit, the plan covers 100% of the cost of all other covered medications. This creates a "safety net" effect that is particularly comforting for those on fixed incomes.

Navigating the cardiovascular loophole

Medicare Part D plans are now required to cover medications like Wegovy when they are prescribed for "medically accepted indications" beyond weight loss. Specifically, these drugs may be covered for beneficiaries with obesity who have established cardiovascular disease, such as a history of heart attack, stroke or peripheral arterial disease.

I recommend a proactive approach to help your clients secure this coverage.

• Review health histories: Identify any history of cardiovascular events in your client files.
• Specialist coordination: Encourage clients to work closely with their doctors to ensure prescriptions are coded for cardiovascular protection.
• Formulary verification: Confirm that the specific medication is listed on the plan’s formulary under the correct cardiovascular tier.

Maximizing the 2026 BALANCE model

The Centers for Medicare and Medicaid Services recently signaled a major strategic shift with the launch of the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive health) model. This voluntary initiative represents the first real crack in the federal ban on anti-obesity medications by pairing GLP-1 access with no-cost lifestyle support.

Medicare beneficiaries are expected to gain access through a short-term demonstration bridge as early as July 2026, with the full model officially integrating into Part D plans in January 2027. Under this framework, pricing for injectable GLP-1s is projected to drop to roughly $245 per month, with beneficiary copays capped at just $50. You should identify which carriers in your specific market are volunteering for this pilot to give your clients a competitive edge.

The fiscal reality: A $35 billion question

The financial implications of these changes are truly staggering. The Congressional Budget Office estimates that expanding coverage to anti-obesity medications will cost Medicare an additional $35 billion through 2034.

Clinical benefits are undeniable, but the CBO warns that long-term health savings will not fully offset this massive initial spend. This "fiscal gap" suggests that while coverage is expanding, Part D premiums may see upward pressure across the board. I advise my clients to prepare for these potential premium shifts even as they enjoy better access to life-changing medications.

Proactive strategies: Your three-step action plan

Help clients avoid the "Medicare cliff"— that jarring moment when they transition from an employer plan to Medicare, only to find their GLP-1 coverage has vanished. KFF data shows 22% of adults aged 50–64 currently use these drugs, yet that number drops to 9% once they hit 65 due to coverage gaps.

You can lead with empathy and authority by implementing this streamlined roadmap during the Special Enrollment Period or upcoming Annual Enrollment Period.

• Audit the "preretiree" book: Review your list of clients aged 60–64 to identify those currently on Zepbound or Wegovy. Check if they meet specific comorbidity criteria, such as established heart disease, which can trigger coverage under the "cardiovascular loophole."
• Verify the $2,100 out-of-pocket cap: Remind clients that the Inflation Reduction Act’s $2,100 cap on Part D prescriptions takes full effect for 2026. If their GLP-1 is covered for a cardiovascular indication, they will quickly hit this cap, effectively making the rest of their annual prescriptions $0.
• Monitor the "TrumpRx" alternative: Watch the emerging TrumpRx platform for clients who do not meet clinical criteria for Medicare coverage. Early reports suggest this model could bypass traditional pharmacy benefit managers to drop cash-pay prices to about $350 per month, providing a vital safety net for those in the gap.

And remember, when reviewing client portfolios during the SEP or anticipating the next AEP, verify if your clients on GLP-1s meet these comorbidity criteria.

The new frontier of obesity care is here. By staying ahead of these regulatory pivots, you aren't just selling a policy; you are securing a client's health and wealth for the long haul.

© Entire contents copyright 2026 by InsuranceNewsNet.com Inc. All rights reserved. No part of this article may be reprinted without the expressed written consent from InsuranceNewsNet.com.

Joe Orsini is president at Network Insurance Senior Health Division and Grupo Latinoamericano de Seguros, both AmeriLife companies. Contact him at [email protected].